您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > TCS JNK 6o
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
TCS JNK 6o
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
TCS JNK 6o图片
CAS NO:894804-07-0
包装与价格：
包装价格(元)
10mM (in 1mL DMSO)电议
1mg电议
5mg电议
10mg电议

产品介绍
TCS JNK 6o (TCS JNK 6o) 是一种 c-Jun N-末端激酶 (JNK-1, -2, and -3) 抑制剂，Ki 值分别为 2 nM, 4 nM, 52 nM，IC50 值为JNK-1 和 -2 分别为 45 nM 和 160 nM。
Cas No.894804-07-0
别名JNK Inhibitor VIII
化学名N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)-2-(2,5-dimethoxyphenyl)acetamide
Canonical SMILESO=C(CC1=CC(OC)=CC=C1OC)NC2=NC(OCC)=C(C#N)C(N)=C2
分子式C18H20N4O4
分子量356.38
溶解度DMF: 10 mg/ml,DMSO: 10 mg/ml,DMSO:PBS(pH 7.2) (1:2): 0.3 mg/ml
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 45 nM for JNK1 and 160 nM for JNK2 [1]

TCS JNK 6o is a ATP-competitive and selective c-Jun N-terminal kinase (JNK) inhibitor. JNKs belong to the mitogen-activated protein kinase (MAP kinase) family, and are responsive to stress stimuli, including ultraviolet irradiation, cytokines, osmotic shock and heat shock. JNKs also play a role in the cellular apoptosis and T cell differentiation pathway.

In vitro: CS JNK 6o, in a dose-dependent manner, inhibits phosphorylation of c-jun (EC50 = 920 nM) and prevents collagen-induced platelet aggregation. At low collagen concentrations (0.2 and 0.5 μg/ml), platelet aggregation was totally or partially impaired by 10 μM CS JNK 6o, whereas at a high collagen concentration (5 μg/ml), TCS JNK 6o had no effect [2].

In vivo:. Pharmacokinetic profiles were studied for TCS JNK 6o in Sprague-Dawley rats. TCS JNK 6o showed a short half-life of about 1 hour, with barely measurable bioavailability and rapid clearance. Microsomal incubation studies revealed that the oxidative metabolism of TCS JNK 6o was very rapid [1]

Clinical trial: So far, no clinical study has been conducted.

References:
[1] Szczepankiewicz BG1, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ, Haasch DL, Wang S, Clampit JE, Johnson EF, Lubben TH, Stashko MA, Olejniczak ET, Sun C, Dorwin SA, Haskins K, Abad-Zapatero C, Fry EH, Hutchins CW, Sham HL, Rondinone CM, Trevillyan JM.  Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
[2] Kauskot A, Adam F, Mazharian A, Ajzenberg N, Berrou E, Bonnefoy A, Rosa JP, Hoylaerts MF, Bryckaert M.  Involvement of the mitogen-activated protein kinase c-Jun NH2-terminal kinase 1 in thrombus formation. J Biol Chem. 2007 Nov 2;282(44):31990-9.